Skip to main content

Advertisement

Log in

Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or abnormal (group II) putamen [123I]FP-CIT DAT (dopamine transporter) binding. In this study we reassessed clinical features and DAT binding in 19 of the original 32 patients (10 of group I and 9 of group II) after a 19–39-month follow-up period and tested the effects of chronic levodopa treatment in both cohorts of patients. In group I patients, [123I]FP-CIT SPET (single photon emission tomography) was still normal in all patients at follow-up; DAT binding and UPDRS (Unified Parkinson’s Disease Rating Scale) motor score values did not differ from baseline. In group II patients, [123I]FP-CIT SPET was still abnormal at follow-up; putamen DAT binding was significantly reduced and UPDRS III score higher compared to baseline. Levodopa treatment improved motor symptoms in three out of ten patients of group I and in eight out of nine patients of group II. No adverse psychiatric effects were observed in any of the patients. This study shows that DAT binding imaging may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals in the context of a progressive degenerative parkinsonism. Patients with DIP may benefit from levodopa therapy, particularly when dopamine nerve terminal defects are present, and this should be considered in the therapeutic management of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Alvarez MV, Evidente VG (2008) Understanding drug-induced parkinsonism: separating pearls from oy-sters. Neurology 70:32–34

    Article  Google Scholar 

  2. Angrist B, Sathananthan G, Gershon S (1973) Behavioural effect of l-dopa in schizophrenic patients. Psychopharmacologia 31:1–11

    Article  PubMed  CAS  Google Scholar 

  3. Benamer HTS, Patterson J, Wyper D, Hadley DM, Macphee GJA, Grosset DG (2000) Correlation of Parkinson’s disease severity and duration with [123I]FP-CIT SPET striatal uptake. Mov Disord 15:692–698

    Article  PubMed  CAS  Google Scholar 

  4. Booij J, Speelman JD, Hornstinkm M, Wolters EC (2001) The clinical benefit of striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with others forms of parkinsonism. Eur J Nucl Med 28:266–272

    Article  PubMed  CAS  Google Scholar 

  5. Bower JH, Maraganore DM, McDonnel SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 52:1214–1220

    PubMed  CAS  Google Scholar 

  6. Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18 F-dopa PET study. Neurology 43:552–556

    PubMed  CAS  Google Scholar 

  7. Davidson M, Keefe RSE, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) l-Dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934–938

    PubMed  CAS  Google Scholar 

  8. Fleming P, Makar H, Hunter KR (1970) Levodopa in drug-induced extrapyramidal disorders. Lancet 2:1186

    Article  PubMed  CAS  Google Scholar 

  9. Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854

    Article  PubMed  CAS  Google Scholar 

  10. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108:1299–1308

    Article  PubMed  CAS  Google Scholar 

  11. Hausner RS (1983) Neuropleptic induced parkinsonism and Parkinson’s disease: differential diagnosis and treatment. J Clin Psychiatry 11:13–16

    Google Scholar 

  12. Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253(Suppl 3):III/22–III/24

    CAS  Google Scholar 

  13. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I] FP/CIT SPET imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 21:510–514

    Article  PubMed  Google Scholar 

  14. Miller LG, Jankovic J (1990) Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 8:525–532

    Google Scholar 

  15. Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson’s disease. Brain 119:2097–2103

    Article  PubMed  Google Scholar 

  16. Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, Nordera G, Moretto G, Fiaschi A, Smania N, Girogetti P, Antonini A (2006) Comparative analysis of visual and semi-quantitative assessment of striatal [123I] FP-CIT-SPET binding in Parkinson’s disease. Neurol Sci 27:397–401

    Article  PubMed  CAS  Google Scholar 

  17. Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):43–51

    Article  Google Scholar 

  18. Scherfler C, Schwarz J, Antonini A, Grosser D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22:1229–1238

    Article  PubMed  Google Scholar 

  19. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Haldin C, Pilowsky LS, Pupi A (2002) European Association of Nuclear Medicine procedure guidelines for brain neurotrasmission SPET using (123)I-labelled dopamine (D2) transporter ligands. Eur J Nucl Med 29:BP30–BP35

    Article  CAS  Google Scholar 

  20. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steimayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, Antonimi A (2008) [123I] FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825–1829

    Article  PubMed  Google Scholar 

  21. Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28–S33

    Article  PubMed  Google Scholar 

  22. Yaryura-Tobias JA, Wolpert A, Dana L, Merlis S (1970) The action of l-dopa on schizophrenic patients, a preliminary report. Curr Ther Res 12:528–531

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to thank Mr. Anthony Steele, former Verona University Senior Lecturer in Medical English, for his invaluable assistance with the linguistic revision of this paper.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Michele Tinazzi or Tommaso Bovi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tinazzi, M., Antonini, A., Bovi, T. et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 256, 910–915 (2009). https://doi.org/10.1007/s00415-009-5039-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-5039-0

Keywords

Navigation